Wick Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$948K Sell
819
-72
-8% -$85K 0.12% 79
2026
Q2
$1.07M Buy
891
+240
+37% +$245K 0.16% 56
2026
Q1
$598K Buy
651
+47
+8% +$47.6K 0.11% 84
2025
Q4
$649K Buy
604
+137
+29% +$131K 0.12% 74
2025
Q3
$357K Sell
467
-1,317
-74% -$980K 0.09% 89
2025
Q2
$364K Buy
1,784
+1,247
+232% +$969K 0.09% 80
2025
Q1
$444K Buy
537
+66
+14% +$54.9K 0.13% 70
2024
Q4
$364K Buy
471
+82
+21% +$67.9K 0.11% 68
2024
Q3
$344K Buy
389
+9
+2% +$8.09K 0.11% 57
2024
Q2
$344K Buy
+380
New +$304K 0.12% 55

Other funds holding LLY

Wick Capital Partners's LLY Position: Q3 2026 in Review

Wick Capital Partners reduced its Eli Lilly (LLY) stake by 8.1% in Q3 2026, selling an estimated $85K and leaving 819 shares worth $948K. The position accounts for 0.12% of the portfolio, ranked #79.

Wick Capital Partners first reported a position in LLY in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.07M in Q2 2026. 4,599 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Wick Capital Partners held 819 shares of Eli Lilly worth $948K as of Q3 2026.
  • Wick Capital Partners sold 72 Eli Lilly shares in Q3 2026, an estimated $85K.
  • Eli Lilly made up 0.12% of Wick Capital Partners's portfolio in Q3 2026, its #79 holding.
  • Wick Capital Partners first reported a position in Eli Lilly in Q2 2024 and has held it in 10 quarters since.
  • Wick Capital Partners's Eli Lilly position peaked at $1.07M in Q2 2026.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Wick Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.